title: Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
abstract: The prognostic relevance of CRLF2 -rearrangements in childhood acute B-cell precursor lymphoblastic leukaemia (ALL), was assessed by a comparative analysis of 114 non-Down-syndrome patients (99 P2RY8-CRLF2+ , 15 IGH@-CRLF2+ ), 76 from the AIEOP-BFM ALL 2000 and 38 from the MRC ALL97 trials. The 6-year cumulative relapse incidence of P2RY8-CRLF2+ patients treated on the two trials was not statistically different: 0·37 ± 0·06 vs. 0·25 ± 0·08 (P = 0·194). In contrast, 0/9 IGH@-CRLF2+ AIEOP-BFM, but 5/6 ALL97 patients relapsed. Conclusively, P2RY8-CRLF2+ patients had an intermediate protocol-independent outcome while the different prognosis of IGH@-CRLF2+ patients could be related to the different structures of the applied treatment protocols.
authors: Paediatric Haematology and Oncology, Department of Paediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria. andishe.attarbaschi@stanna.at
authors: Andishe
authors: A
authors: Attarbaschi
authors: Maria
authors: M
authors: Morak
authors: Gunnar
authors: G
authors: Cario
authors: Giovanni
authors: G
authors: Cazzaniga
authors: Hannah M
authors: HM
authors: Ensor
authors: Truus
authors: T
authors: te Kronnie
authors: Jutta
authors: J
authors: Bradtke
authors: Georg
authors: G
authors: Mann
authors: Elena
authors: E
authors: Vendramini
authors: Chiara
authors: C
authors: Palmi
authors: Claire
authors: C
authors: Schwab
authors: Lisa J
authors: LJ
authors: Russell
authors: Martin
authors: M
authors: Schrappe
authors: Valentino
authors: V
authors: Conter
authors: Christopher D
authors: CD
authors: Mitchell
authors: Sabine
authors: S
authors: Strehl
authors: Martin
authors: M
authors: Zimmermann
authors: Ulrike
authors: U
authors: Pötschger
authors: Christine J
authors: CJ
authors: Harrison
authors: Martin
authors: M
authors: Stanulla
authors: Renate
authors: R
authors: Panzer-Grümayer
authors: Oskar A
authors: OA
authors: Haas
authors: Anthony V
authors: AV
authors: Moorman
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D008297:Male; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D018121:Receptors, Cytokine / Q000032:analysis*; D012008:Recurrence; D012074:Remission Induction; D012306:Risk; D016896:Treatment Outcome
chemical_list: C498762:CRLF2 protein, human; D018121:Receptors, Cytokine